Dried blood spot

Roche launches the first infectious disease tests and cobas omni Utility Channel for use on the cobas 5800 System in countries accepting the CE Mark

Retrieved on: 
Wednesday, December 15, 2021
DJSI, Roche Diagnostics, Hoffmann-La Roche, RNA, Genentech, PCR, Molecule, HIV-1, Essential medicines, Severe acute respiratory syndrome coronavirus 2, LDT, Diagnosis, Utility, Automation, Genome, Stanford University v. Roche Molecular Systems, Inc., World, IVD, LIS, Time, HIV, Plasma, Serum, Dow Jones, RO, Dried blood spot, Patient, HBV, Infection, Laboratory, CE, Joint Medical Service (Germany), HIV-2, Cobas, Ophthalmology, HCV, Central nervous system, CHF, ROG, Fine chemical, Medical imaging, Vaccine, Chugai Pharmaceutical Co., System

The cobas 5800 System will offer the same menu as the cobas 6800 and 8800 Systems.

Key Points: 
  • The cobas 5800 System will offer the same menu as the cobas 6800 and 8800 Systems.
  • Roche is pursuing CE approval for continued menu expansion on the cobas 5800 System, including cobas SARS-CoV-2, through early-to-mid 2022.
  • Roche anticipates tests to be available beyond CE markets in additional countries in 2022.
  • The cobas omni Utility Channel on the cobas 5800 System enables a broader testing menu by consolidating open channel assays with Roche in vitro diagnostic (IVD) assays on a single platform.

Roche launches the first infectious disease tests and cobas omni Utility Channel for use on the cobas 5800 System in countries accepting the CE Mark

Retrieved on: 
Wednesday, December 15, 2021
DJSI, Hepatitis B, Roche Diagnostics, Hoffmann-La Roche, RNA, Genentech, PCR, Death, Molecule, HIV-1, Essential medicines, Severe acute respiratory syndrome coronavirus 2, LDT, Infection, Diagnosis, Utility, Automation, Genome, Stanford University v. Roche Molecular Systems, Inc., World, Running, IVD, LIS, Time, HIV, Plasma, Serum, Dow Jones, RO, Dried blood spot, Patient, HBV, Laboratory, CE, Joint Medical Service (Germany), HIV-2, Cobas, Ophthalmology, HCV, Central nervous system, CHF, ROG, Vaccine, Fine chemical, Medical imaging, Chugai Pharmaceutical Co., System

PLEASANTON, Calif., Dec. 15, 2021 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the first infectious disease tests on the cobas® 5800 System, a new molecular laboratory instrument, in countries accepting the CE mark. These include cobas® HIV-1, cobas® HBV, cobas® HCV, cobas® HIV-1/HIV-2 Qualitative, and the cobas omni Utility Channel kit. These launches expand the Roche Molecular portfolio offering by providing standardised performance and efficiencies across low, medium and high volume molecular laboratory testing needs.

Key Points: 
  • PLEASANTON, Calif., Dec. 15, 2021 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the first infectious disease tests on the cobas 5800 System, a new molecular laboratory instrument, in countries accepting the CE mark.These include cobas HIV-1, cobas HBV, cobas HCV, cobas HIV-1/HIV-2 Qualitative, and the cobas omni Utility Channel kit.
  • The cobas 5800 System will offer the same menu as the cobas 6800 and 8800 Systems.
  • Roche is pursuing CE approval for continued menu expansion on the cobas 5800 System, including cobas SARS-CoV-2, through early-to-mid 2022.
  • The cobas omni Utility Channel on the cobas 5800 System enables a broader testing menu by consolidating open channel assays with Roche in vitro diagnostic (IVD) assays on a single platform.

Global Dried Blood Spot Collection Cards Market (2020 to 2027) - Share, Size, Trends, Industry Analysis Report

Retrieved on: 
Monday, February 22, 2021
Neonatology, Health sciences, Health, Blood tests, Epidemiology, Rare diseases, Medical software, Qiagen, Dried blood spot, PerkinElmer, Newborn screening, Medicine

The global dried blood spot collection cards market expected to reach USD 339.5 million by 2027, according to the study.

Key Points: 
  • The global dried blood spot collection cards market expected to reach USD 339.5 million by 2027, according to the study.
  • The recent surge in COVID-19 pandemic, rising newborn screening through dried blood spot collection cards for hereditary and metabolic disorders, innovations, and its wide applicability in diagnosing varied diseases coupled with new product launches are few factors attributed to the market growth for dried blood spot collection cards.
  • The global dried blood spot collection cards industry is fragmented based on card type, application, and region.
  • Qiagen, PerkinElmer, and Roche Diagnostics are a few of the major market players operating in the dried blood spot collection cards industry.

Outlook on the Dried Blood Spot Collection Cards Global to 2027 - by Type, Application and Regions - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 18, 2021
Medical Supplies, Health, Neonatology, Epidemiology, Rare diseases, Blood tests, Health sciences, Dried blood spot, Health, Newborn screening, Medicine

The global dried blood spot collection cards market expected to reach USD 339.5 million by 2027, according to the study.

Key Points: 
  • The global dried blood spot collection cards market expected to reach USD 339.5 million by 2027, according to the study.
  • The recent surge in COVID-19 pandemic, rising newborn screening through dried blood spot collection cards for hereditary and metabolic disorders, innovations, and its wide applicability in diagnosing varied diseases coupled with new product launches are few factors attributed to the market growth for dried blood spot collection cards.
  • The global dried blood spot collection cards industry is fragmented based on card type, application, and region.
  • Based on application, the global dried blood spot collection cards industry is further bifurcated into newborn screening, infectious disease testing, therapeutic drug monitoring, forensics, and other applications.

ProterixBio announces commercial availability of a quantitative COVID-19 serology test validated for dried blood spots from a finger stick

Retrieved on: 
Thursday, February 11, 2021
Medical specialties, Branches of biology, Clinical medicine, Hematology, Blood tests, Immunologic tests, Epidemiology, Serology, Blood plasma, Heparin, Dried blood spot, Neutralizing antibody

BILLERICA, Mass., Feb. 11, 2021 /PRNewswire/ --ProterixBio, Inc. announced today commercial availability of a quantitative COVID-19 serology assay that has been validated for dried blood spots (DBS) from a finger stick.

Key Points: 
  • BILLERICA, Mass., Feb. 11, 2021 /PRNewswire/ --ProterixBio, Inc. announced today commercial availability of a quantitative COVID-19 serology assay that has been validated for dried blood spots (DBS) from a finger stick.
  • ProterixBio has one of the only COVID-19 serology tests that provides a quantitative measurement of antibody levels associated with neutralizing activity and that has been validated with dried blood spots.
  • The test has been validated in a variety of sample types, including serum, EDTA-plasma, heparin-plasma and, most recently, dried blood spots from a finger stick.
  • "The ability to perform this test on finger stick samples increases test accessibility by allowing easier, more convenient specimen collection by health care providers."

Aptima® HIV-1 Quant Dx Assay Awarded WHO Prequalification for Dried Blood Spot Samples

Retrieved on: 
Monday, September 14, 2020
Infectious diseases, Science, Health, Research, Medical specialties, Health, HIV/AIDS, Articles, Virology, Medical tests, Pandemics, Dried blood spot, Viral load, Diagnosis of HIV/AIDS, HIV, Assay, Hologic’s Global Access Initiative, Hologic

Hologic, Inc. (Nasdaq: HOLX) announced today that its CE-marked Aptima HIV-1 Quant Dx assay has been awarded World Health Organization (WHO) prequalification for testing of dried blood spot (DBS) samples.

Key Points: 
  • Hologic, Inc. (Nasdaq: HOLX) announced today that its CE-marked Aptima HIV-1 Quant Dx assay has been awarded World Health Organization (WHO) prequalification for testing of dried blood spot (DBS) samples.
  • The Aptima HIV-1 Quant Dx assay can be used with DBS samples to monitor viral load and disease progression among HIV-1 infected individuals, and to aid in the diagnosis of HIV-1 infected infants under 18 months.
  • DBS samples are more stable and easily transportable compared to liquid whole blood or plasma samples.
  • The DBS samples do not require refrigeration and when stored properly can withstand extreme conditions, including excess heat and humidity.

ZRT Laboratory Launches COVID-19 IgG Dual Antibody Test in Dried Blood Spot

Retrieved on: 
Wednesday, July 8, 2020
Branches of biology, Glycoproteins, Medicine, Medical specialties, Immunology, Blood tests, Dried blood spot, Antibody, Immunoglobulin G, Laboratory Developed Test, Clinical Laboratory Improvement Amendments

Blood is then dried and shipped without coolants directly to ZRT laboratory for testing.

Key Points: 
  • Blood is then dried and shipped without coolants directly to ZRT laboratory for testing.
  • ZRT Laboratory is a CLIA-certified high complexity testing facility, and all dried blood spot assays, including our new COVID-19 IgG Dual Antibody Test, are stringently validated as laboratory developed tests (LDTs) according to FDA guidelines.
  • ZRT has >15 years' expertise in finger stick dried blood spot analysis, testing a wide range of hormones, cardiometabolic risk markers, vitamin D and essential elements.
  • To learn more about ZRT's dried blood spot testing visit http://www.zrtlab.com/sample-types/blood-spot/ or the new COVID-19 IgG dual antibody test, visit http://www.zrtlab.com/test-specialties/covid-19-igg-dual-antibody/ or contact customer service at 866.600.1636 or email [email protected] .

Symbiotica and InTeleLabs Launch the First At-Home Self-Collection COVID-19 Antibody Test Using a Small Amount of Blood

Retrieved on: 
Tuesday, June 16, 2020
Medical Supplies, Health, Infectious diseases, Other Health, General Health, Biotechnology, Medical specialties, Medicine, Branches of biology, Immunology, Blood tests, Immunologic tests, Antibody, Glycoproteins, Dried blood spot, ELISA, Diagnosis of HIV/AIDS, Symbiotica, InTeleLabs

We are excited to be the first to offer an accurate home collection antibody test as the nation continues to fight this deadly virus, said Erik Hennings, CEO of InTeleLabs.

Key Points: 
  • We are excited to be the first to offer an accurate home collection antibody test as the nation continues to fight this deadly virus, said Erik Hennings, CEO of InTeleLabs.
  • Our test is an important tool to help identify children and adults who have been infected with the virus and developed an immune response to COVID-19.
  • The testing process was designed to be easy-to-use by obtaining small blood droplets collected on a dried blood spot (DBS) card from a simple, finger pinprick test.
  • For more information about the COVID-19 Immune Response Antibody test, or other available lab tests on elicity, visit https://www.elicity.health .

Epigenetic Immune Cell Diagnostic Tool Shows Promise In Detecting Severe Immune Diseases Not Currently Identified In Newborn Screenings

Retrieved on: 
Wednesday, August 1, 2018
Medicine, Immunodeficiency, Primary immunodeficiency, Clinical medicine, Combined immunodeficiencies, Dried blood spot, Severe combined immunodeficiency, Anatomy, Rare diseases

BETHESDA, Md., Aug. 1, 2018 /PRNewswire/ --A novel diagnostic approach using epigenetic immune monitoring to screen newborns for inherited diseases could expand the number of life-threatening immune deficiencies identified in newborns.

Key Points: 
  • BETHESDA, Md., Aug. 1, 2018 /PRNewswire/ --A novel diagnostic approach using epigenetic immune monitoring to screen newborns for inherited diseases could expand the number of life-threatening immune deficiencies identified in newborns.
  • Newborns are routinely screened for inheritable diseases by analyzing dried blood spots (DBS) from blood taken from a heel-prick.
  • Among the more than 300 known primary immune deficiencies (PIDs), only Severe Combined Immunodeficiencies (SCID) are detected at birth with the current technology used to analyze the DBS.
  • Applied to DBS, epigenetic immune cell quantification was shown to identify newborns suffering from various primary immunodeficiencies.